Cheng Lyu

Cheng Lyu

Auto-generated profile, based on publicly available information

Cheng Lyu

Department of Biomedical Engineering School of Medicine Tsinghua‐Peking Center for Life Sciences Tsinghua University Beijing 100084 China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2022 in Advanced Science
Verified
Journal Article
Open access
PZPeng Zhao
Peng Zhao
TSTian Sun
Tian Sun
CLCheng Lyu
Cheng Lyu
KLKaini Liang
Kaini Liang
YNYudi Niu
Yudi Niu
YDYanan Du
Yanan Du
Deposition of extracellular matrix (ECM) in the liver is an important feature of liver cirrhosis. Recovery from liver cirrhosis is physiologically challenging, partially due to the ECM in scar tissue showing resistance to cell‐mediated degradation by secreted matrix metalloproteinases (MMPs). Here, a cell‐mediated ECM‐degradation screening system (CEDSS) in vitro is constructed for high‐throughput searching for cells with tremendous degradation ability. ECM‐degrading liver sinusoidal endothelial cells (dLSECs) are screened using CEDSS, which exhibit 17 times the ability to degrade collagen when compared to other cells. The degradation ability of dLSECs is mediated by the upregulation of MMP9. In particular, mRNA expression of MMP9 shows an 833‐fold increase in dLSECs compared to normal endothelial cells (nLSECs), and MMP9 is regulated by transcription factor c‐Fos. In vivo, single intrasplenic injection of dLSECs alleviates advanced liver fibrosis in mice, while intraperitoneal administration of liver‐targeting peptide‐modified dLSECs shows enhanced fibrosis‐targeting effects. Degradative human umbilical vein endothelial cells (dHUVECs) prove their enhanced potential of clinical translation. Together, these results highlight the potential of ECM‐degrading endothelial cells in alleviating advanced liver fibrosis, thus providing remarkable insights in the development of ECM‐targeting therapeutics.

23 May 2025 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
LZLyu Zhou
Lyu Zhou
ZSZiao Shi
Ziao Shi
XYXuesi Yang
Xuesi Yang
JZJia’nAn Zeng
Jia’nAn Zeng
ZYZhifeng You
Zhifeng You
YDYanan Du
Yanan Du

29 April 2023 in Advanced Science
Verified
Journal Article
Open access
PZPeng Zhao
Peng Zhao
TSTian Sun
Tian Sun
CLCheng Lyu
Cheng Lyu
YDYanan Du
Yanan Du